Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $8,250 | 3 | 95.2% |
| Food and Beverage | $417.59 | 12 | 4.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Aqua Pharmaceuticals | $8,250 | 3 | $0 (2017) |
| Gilead Sciences, Inc. | $245.27 | 2 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $96.41 | 6 | $0 (2019) |
| GlaxoSmithKline, LLC. | $22.59 | 1 | $0 (2024) |
| Eisai Inc. | $21.00 | 1 | $0 (2020) |
| Encore Dermatology Inc. | $17.32 | 1 | $0 (2018) |
| Galderma Laboratories, L.P. | $15.00 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $267.86 | 3 | Gilead Sciences, Inc. ($245.27) |
| 2020 | $21.00 | 1 | Eisai Inc. ($21.00) |
| 2019 | $14.66 | 1 | AstraZeneca Pharmaceuticals LP ($14.66) |
| 2018 | $98.19 | 6 | AstraZeneca Pharmaceuticals LP ($65.87) |
| 2017 | $8,266 | 4 | Aqua Pharmaceuticals ($8,250) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/16/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $22.59 | General |
| Category: ONCOLOGY | ||||||
| 09/10/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $124.98 | General |
| Category: HIV | ||||||
| 05/07/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $120.29 | General |
| Category: HIV | ||||||
| 09/09/2020 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $21.00 | General |
| Category: Oncology | ||||||
| 02/09/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: Oncology | ||||||
| 10/30/2018 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $12.86 | General |
| Category: Oncology | ||||||
| 08/28/2018 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $13.79 | General |
| Category: Oncology | ||||||
| 05/30/2018 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $19.32 | General |
| Category: Oncology | ||||||
| 04/12/2018 | Galderma Laboratories, L.P. | EPIDUO FORTE (Drug), ORACEA, SOOLANTRA | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: ACNE | ||||||
| 01/26/2018 | Encore Dermatology Inc. | Impoyz (Drug) | Food and Beverage | In-kind items and services | $17.32 | General |
| Category: Dermatology Plaque Psoriasis | ||||||
| 01/23/2018 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $19.90 | General |
| Category: Oncology | ||||||
| 11/15/2017 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: Oncology | ||||||
| 05/05/2017 | Aqua Pharmaceuticals | — | Honoraria | Cash or cash equivalent | $2,000.00 | General |
| 04/19/2017 | Aqua Pharmaceuticals | — | Honoraria | Cash or cash equivalent | $2,750.00 | General |
| 01/09/2017 | Aqua Pharmaceuticals | — | Honoraria | Cash or cash equivalent | $3,500.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 252 | 277 | $163,832 | $38,252 |
| 2022 | 6 | 621 | 2,060 | $528,324 | $159,895 |
| 2021 | 4 | 539 | 2,173 | $504,057 | $155,166 |
| 2020 | 5 | 646 | 2,425 | $508,908 | $163,165 |
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 217 | 231 | $146,989 | $34,241 | 23.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 20 | 20 | $10,327 | $2,252 | 21.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 15 | 26 | $6,516 | $1,759 | 27.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 243 | 1,525 | $306,041 | $92,758 | 30.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 197 | 207 | $125,407 | $37,845 | 30.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 134 | 281 | $79,651 | $23,895 | 30.0% |
| 99220 | Initial hospital observation care per day, typically 70 minutes | Facility | 2022 | 22 | 22 | $10,604 | $3,579 | 33.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 12 | 12 | $5,190 | $1,388 | 26.7% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 13 | 13 | $1,431 | $430.90 | 30.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 254 | 1,688 | $337,869 | $102,893 | 30.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 157 | 342 | $95,898 | $30,529 | 31.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 113 | 119 | $67,771 | $20,945 | 30.9% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 15 | 24 | $2,520 | $799.20 | 31.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 277 | 1,806 | $361,389 | $115,007 | 31.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 113 | 120 | $66,353 | $21,629 | 32.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 97 | 140 | $39,296 | $12,853 | 32.7% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 145 | 345 | $36,477 | $11,962 | 32.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 14 | 14 | $5,393 | $1,714 | 31.8% |
About Dr. Christopher Ho, MD
Dr. Christopher Ho, MD is a Pulmonary Disease healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/29/2005. The National Provider Identifier (NPI) number assigned to this provider is 1578563797.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Ho, MD has received a total of $8,668 in payments from pharmaceutical and medical device companies, with $267.86 received in 2024. These payments were reported across 15 transactions from 7 companies. The most common payment nature is "Honoraria" ($8,250).
As a Medicare-enrolled provider, Ho has provided services to 2,058 Medicare beneficiaries, totaling 6,935 services with total Medicare billing of $516,477. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Practice Information
- Specialty Pulmonary Disease
- Location Los Angeles, CA
- Active Since 07/29/2005
- Last Updated 12/03/2009
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1578563797
Products in Payments
- Biktarvy (Drug) $245.27
- TAGRISSO (Drug) $96.41
- JEMPERLI (Biological) $22.59
- Lenvima (Drug) $21.00
- Impoyz (Drug) $17.32
- EPIDUO FORTE (Drug) $15.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Los Angeles
Prof. Toby Maher, Md, MD
Pulmonary Disease — Payments: $1.1M
Donald Tashkin, Md, MD
Pulmonary Disease — Payments: $646,650
Rajan Saggar, Md, MD
Pulmonary Disease — Payments: $426,392
John Belperio, Md, MD
Pulmonary Disease — Payments: $308,808
Christopher Cooper, Md, MD
Pulmonary Disease — Payments: $207,817
Robert Strieter, Md, MD
Pulmonary Disease — Payments: $172,942